Jorge Sierra

39.3k total citations · 2 hit papers
456 papers, 15.0k citations indexed

About

Jorge Sierra is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Jorge Sierra has authored 456 papers receiving a total of 15.0k indexed citations (citations by other indexed papers that have themselves been cited), including 244 papers in Hematology, 136 papers in Oncology and 80 papers in Genetics. Recurrent topics in Jorge Sierra's work include Hematopoietic Stem Cell Transplantation (159 papers), Acute Myeloid Leukemia Research (139 papers) and Lymphoma Diagnosis and Treatment (70 papers). Jorge Sierra is often cited by papers focused on Hematopoietic Stem Cell Transplantation (159 papers), Acute Myeloid Leukemia Research (139 papers) and Lymphoma Diagnosis and Treatment (70 papers). Jorge Sierra collaborates with scholars based in Spain, United States and France. Jorge Sierra's co-authors include Rodrigo Martino, Salut Brunet, Frederick R. Appelbaum, Javier Briones, Hartmut Döhner, Anna Sureda, Miguel Á. Sanz, Dietger Niederwieser, Martin S. Tallman and Gert J. Ossenkoppele and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Jorge Sierra

439 papers receiving 14.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

2009 2.4k citations Hartmut Döhner, Elihu H. Estey et al. Blood profile →
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission

2009 604 citations Jorge Sierra, Frederick R. Appelbaum et al. profile →

Peers

Countries citing papers authored by Jorge Sierra

Since Specialization

Citations

This map shows the geographic impact of Jorge Sierra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge Sierra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge Sierra more than expected).

Fields of papers citing papers by Jorge Sierra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jorge Sierra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge Sierra. The network helps show where Jorge Sierra may publish in the future.

Co-authorship network of co-authors of Jorge Sierra

This figure shows the co-authorship network connecting the top 25 collaborators of Jorge Sierra. A scholar is included among the top collaborators of Jorge Sierra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorge Sierra. Jorge Sierra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prevalence of Fms‐Like Tyrosine Kinase 3 (FLT3) Mutations in Patients With Acute Myeloid Leukaemia: A Systematic Literature Review and Meta‐Analysis 2025 ·Cancer Medicine ·(unknown), Naval Daver, (unknown), Bhavik J. Pandya, Bosny Pierre‐Louis, (unknown), Jorge Sierra	0
2	HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma 2025 ·Blood ·A Caballero, (unknown), (unknown), (unknown), (unknown), (unknown), Irene García‐Cadenas, Albert Esquirol, Rodrigo Martino, (unknown), (unknown), José Manuel Soria, (unknown), E. Moreno, (unknown), Jorge Sierra, (unknown), (unknown), Javier Briones	0
3	Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil 2024 ·Transplantation and Cellular Therapy ·Albert Esquirol, María Pascual, Juan Montoro, José Luís Piñana, Christelle Ferrá, (unknown), Irene García‐Cadenas, Aitana Balaguer‐Roselló, Ariadna Pérez, (unknown), (unknown), (unknown), Juan Carlos Hernández‐Boluda, (unknown), Rafael Hernani, Jaime Sanz, Carlos Solano, Jorge Sierra, Rodrigo Martino	0
4	Efficacy and Safety of Reduced-Doses of Post-Transplant Cyclophosphamide in Matched Peripheral Blood Stem Cell Transplantation, a Multicenter Study 2024 ·Blood ·(unknown), (unknown), Andrés Gómez‐De León, Irene García‐Cadenas, (unknown), Perla R. Colunga‐Pedraza, (unknown), Cesar Homero Gutiérrez‐Aguirre, José Carlos Jaime‐Pérez, Jorge Sierra, (unknown), Javier Briones, David Gómez‐Almaguer, Rodrigo Martino	0
5	mRNA-1273 SARS-CoV-2 vaccine in recently transplanted allogeneic hematopoietic cell transplant recipients: Dynamics of cellular and humoral immune responses and booster effect 2023 ·Leukemia Research ·(unknown), (unknown), (unknown), Esther Moga, Sílvia Vidal, (unknown), (unknown), (unknown), (unknown), (unknown), Iria González, Joaquín López‐Contreras, Albert Esquirol, Jorge Sierra, Rodrigo Martino, Irene García‐Cadenas	2
6	Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort 2023 ·Blood Cancer Journal ·(unknown), Marta Pratcorona, Ana Garrido, (unknown), Álex Bataller, Mar Tormo, Montserrat Arnán, Susana Vives, Rosa Coll, Olga Salamero, Ferran Vall‐Llovera, Antònia Sampol, (unknown), Marta Cervera, (unknown), Joan Bargay, Xavier Ortı́n, Josep Nomdedéu, Jordi Esteve, Jorge Sierra, (unknown)	9
7	Feasibility of a New Model of Care for Allogeneic Stem Cell Transplantation Recipients Facilitated by eHealth: The MY-Medula Pilot Study 2023 ·Transplantation and Cellular Therapy ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), E. Moreno, (unknown), (unknown), (unknown), (unknown), Iria González, Jorge Sierra, Rodrigo Martino, Irene García‐Cadenas	5
8	Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1 2021 ·Blood Advances ·(unknown), Álex Bataller, Ana Garrido, Montserrat Hoyos, Montserrat Arnán, Susana Vives, Rosa Coll, Mar Tormo, Antònia Sampol, Lourdes Escoda, Olga Salamero, (unknown), Joan Bargay, (unknown), Josep Nomdedéu, Jordi Esteve, Jorge Sierra, Marta Pratcorona	19
9	Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5‐azacytidine: Identification of responding patients 2019 ·European Journal Of Haematology ·(unknown), Ana Garrido, (unknown), Elena Bussaglia, Marta Pratcorona, (unknown), Ignasi Gich, Montserrat Hoyos, Albert Esquirol, Irene García‐Cadenas, Salut Brunet, Rodrigo Martino, Jorge Sierra, Josep Nomdedéu	6
10	Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy 2018 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Carolina Cuéllar‐García, (unknown), (unknown), (unknown), (unknown), Salut Brunet, Javier Briones, (unknown), Albert Esquirol, Miquel Granell, Silvana Saavedra, Josep Nomdedéu, Jorge Sierra, Rodrigo Martino, Carol Moreno	2
11	A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia 2018 ·Leukemia & lymphoma ·Montserrat Torrebadell, Marina Díaz‐Beyá, Susana G. Kalko, Marta Pratcorona, Josep Nomdedéu, Alfons Navarro, Bernat Gel, Salut Brunet, Jorge Sierra, Mireia Camós, Jordi Esteve	16
12	The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma 2018 ·OncoImmunology ·(unknown), (unknown), A Caballero, Robert G. Schaub, Jorge Sierra, Javier Briones	5
13	Impact of dose intensity on unrelated cord blood transplantation outcomes in adults patients with acute leukemia: A Report from Eurocord, the ALWP and the Cord Blood Committee of the CTIWP of the EBMT 2016 ·Bone Marrow Transplantation ·F Baron, Annalisa Ruggeri, Eric Beohou, Myriam Labopin, Guillermo Sanz, Nöel Milpied, M Michallet, Gèrard Socié, Didier Blaise, Jorge Sierra, J.J. Cornelissen, Mohamad Mohty, Christoph Schmid, Sebastian Giebel, Norbert Claude Gorin, Jordi Esteve, Fabio Ciceri, Bipin N. Savani, Éliane Gluckman, Arnon Nagler	1
14	Toward a post-conflict Colombia: restoring to the future 2015 ·(unknown), Jorge Sierra, Wilson Ramírez, Orlando Vargas Ríos, Zoraida Calle, (unknown), Carolina Murcia, James Aronson, (unknown)	21
15	Myndus crudus : vector del agente causante de la marchitez letal en palma de aceite en Colombia 2011 ·Revista Palmas ·(unknown), (unknown), Jorge Sierra, Gerardo Martínez	8
16	Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome 2010 ·Journal of Clinical Oncology ·Brian McClune, Daniel J. Weisdorf, Tanya L. Pedersen, Gisela Tunes da Silva, Martin S. Tallman, Jorge Sierra, John F. DiPersio, Armand Keating, Robert Peter Gale, Biju George, Vikas Gupta, Theresa Hahn, Luis Isola, Madan Jagasia, Hillard M. Lazarus, David I. Marks, Richard T. Maziarz, Edmund K. Waller, Christopher Bredeson, Sergio Giralt	338
17	Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study 2010 ·Journal of Clinical Oncology ·Anjali S. Advani, Bertrand Coiffier, Myron S. Czuczman, Martin Dreyling, James M. Foran, Eva Giné, Christian Gisselbrecht, Nicolas Ketterer, Sunita D. Nasta, A. Z. S. Rohatiner, Ingo G.H. Schmidt‐Wolf, Martin Schüler, Jorge Sierra, Mitchell R. Smith, Gregor Verhoef, Jane N. Winter, Joseph Boni, Erik Vandendries, Mark Shapiro, Luis Fayad	255
18	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet breakdown → 2009 ·Blood ·Hartmut Döhner, Elihu H. Estey, Sergio Amadori, Frederick R. Appelbaum, Thomas Büchner, Alan K. Burnett, Hervé Dombret, Pierre Fenaux, David Grimwade, Richard A. Larson, Francesco Lo‐Coco, Tomoki Naoe, Dietger Niederwieser, Gert J. Ossenkoppele, Miguel Á. Sanz, Jorge Sierra, Martin S. Tallman, Bob Löwenberg, Clara D. Bloomfield	2350
19	Bone Marrow Purging in Acute Lymphoblastic Leukemia: Biological and Clinical Features 1994 ·Journal of Hematotherapy ·Joan Garcı́a, (unknown), (unknown), (unknown), B Amill, (unknown), R Ayats, (unknown), Rosa Gilabert, Jorge Sierra, (unknown), (unknown), (unknown), (unknown), (unknown)	14
20	Hematological Recovery after Autologous Bone Marrow Transplantation in Acute Leukemia: Predictive Factors 1993 ·Journal of Hematotherapy ·(unknown), Jesús M. López Martí, (unknown), Jorge Sierra, (unknown), A Grañena, A Domingo, J Cubells, (unknown), Isabel Badell, (unknown), (unknown), (unknown)	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact